Novo is charging Iran twice as much as the UK for its advanced insulin products according to studies and more than five times the production cost. International organisations and experts are accusing Novo of unethical profiteering in a country marred by sanctions and widespread poverty. Iran as well as patients are under increasing pressure.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed